Zimbabwe has rejected a major US health deal valued at $367m (£272m) over five years because of the United States' request for confidential biological samples.
This move came to light following a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesperson has since clarified that the United States was requesting genetic material for scientific study and commercial purposes while was unwilling to share the benefits from any future vaccines.
"We are forced to start the difficult and regrettable task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued talks to find a deal agreeable to all parties so the country's vital HIV treatment initiative can continue.
Broader Context
This development comes after a similar case in Kenya, where a court blocked a related deal with the US following concerns were filed about the safety of citizens' medical information.
After resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
Based on reports, Sixteen African countries have so far agreed to similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, with no equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the final treatments would be accessible to our population should a new health crisis arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting systems already established via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with potential global health emergencies.
"This framework is intended to ensure that when a country contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how subsequent co-operation could be structured in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
Medical experts stated it understood the official position, but recommended that negotiations need to persist considering a large portion of the nation's HIV programmes were funded by foreign aid.
"In cases where specific concerns arise, such as those involving information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
The situation emphasises the ongoing debate between accepting vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.